• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
+49 (0) 69 / 606 278 – 0
[email protected]
Contact form
Patentanwaltskanzlei

Patentanwaltskanzlei

  • Deutsch

+49 (0) 69 / 606 278 – 0

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • xing
  • Email
MENUMENU
  • Services
    • Advice On Protective IP Rights
    • Patent Application /TM Registration
    • Enforcement Of IP Rights
    • Defence Against IP Rights Enforcement
    • Costs
  • Company
    • Fields of Law
      • Patent Law
      • Utility Model Law
      • Employees‘ Inventions
      • Trademark Law
      • Design Law
      • Trademark and Product Piracy
      • Expert Opinions
    • Our Law Firm
      • Dr. Tim Meyer-Dulheuer
      • Dr. Klaus Zimmermann
      • Zhichao Ying
      • Walter Benjamin Feldheim
    • Commitment
  • Contact
    • Where To Find Us
    • Write us!
    • Request call back
  • Blog

Next step in Battle over CRISPR technology: EPO revokes important patent

6. February 2018

A few days ago, an important patent decision was made to coincide with World Cancer Day and yet relatively unnoticed. The European Patent Office revoked an EU patent for the CRISPR genome processing, which is regarded as a key technology in the fight against cancer.

The grant of patents in CRISPR technology has been a bitterly contested case for years with additional implications due to different patent applications in the EU and the USA. The fact that an important EU patent (2771468 B1) of the leading U.S. Board Institute has now been revoked could call into question further granted European patents. This would reopen the already decided race for the inventor rights of the Board Institute of MIT and Harvard to CRISPR technology.

The facts of the case

genetic scissorBasically, two groups of inventors and, at the same time, two of major American universities are irreconcilably opposed to each other: Broad Institute of MIT and Harvard with inventor Feng Zhang against the University of California Berkeley with inventors Jennifer Doudna and Emmanuelle Charpentier.
In May 2012, Doudna and Charpentier described their “invention” of CRISPR-Cas as a genome editing technique in a scientific publication, more generally known as genetic scissors. In the same year, the University of California filed a patent application for Doudna and Charpentier with the U. S. Patent and Trademark Office (USPTO). The described procedure was an absolute new discovery and can be applied to a wide variety of cells.

Feng Zhang from the Broad Institute of MIT (Masschusetts Institute of Technology) and Harvard University, together with his team, also published on CRISPR but not until 2013 and immediately filed a patent application. This happened a few months later than Doudna and Charpentier’s patent application. Zhang and his team had used CRISPR in eukaryotic, therefore mouse and human cells for the first time.

The U. S. Patent Office granted the team Zhang the patent for the lucrative CRISPR applications in “higher” organisms (eukaryotes) because it recognized an improvement over the method of Doudna and Charpentier. Jennifer Doudna and Emmanuelle Charpentier received the patent for the process. The University of California has appealed against the decision, which was rejected in 2017 in the first review, but is still ongoing – the result is open.

EPO revokes important CRISPR patent of the Board Institute

The revoked patent is important for the Board Institute because it contains several references to older patent rights. The European Patent Office (EPO) justified the revocation with two arguments:
On the one hand, it was about the registered names of the inventors. As the European patent registration failed to include the co-inventor Luciano Marraffini of Rockefeller, the European Patent Office recognised that the patent was invalid. However, the same dispute between Rockefeller and the Board Institute was settled in 2017 in the USA by an arbitration tribunal in favor of the Board Institute.
In addition, the EPO does not recognise the same priority data for inventions as the U.S. Patent Office (USPSTO). The Board Institute wanted to prove with the revoked patent that earlier data from its U.S. patents lie ahead of other patents applied for in Europe.
The Boad Institute intends to appeal the decision to the Board of Appeal of the EPO.

Open patent portfolio as a way out of the CRISPR permanent conflict

KrebsSince last year, the Board Institute has also positioned itself as a generous patent shareholder. Opportunities were sought to make CRISPR genome processing technology widely available for research as it may be the key technology for cancer treatment. The Board Institute manages a CRISPR-Cas9 patent portfolio with major CRISPR-Cas9 patents in the United States and Europe related to the use of CRISPR-Cas9 in eukaryotic cells. They grant non-exclusive licenses for their intellectual property CRISPR/Cas to researching non-profit organizations and universities for a period of two years. They also participate in the MPEG LA organization (to which among others Apple, France Télécom, Fraunhofer-Gesellschaft e. V., Mitsubishi Electric, Sony, US Philips and Microsoft have rights), which manages international patent pools. This is also important, because while the two inventor groups are relentlessly fighting each other, in China the CRISPR process is already being tried out in practice, as the MIT Technlogy Review reported. And at the University of Pennsylvania, doctors are on the verge of starting a clinical trial with CRISPR to strengthen human immune cells against cancerous tumors.

New patents in the CRISPR area

In any case, both competitors are trying to manifest their inventor’s rights with further new patents. In November 2017, for example, Excision BioTherapeutics has been the first to exclusively license the new CRISPR systems discovered by Jennifer Doudna’s group in 2016. This system works with smaller proteins than the previous Cas9 proteins (CasY and CasX). And the Board Institute secured a patent on CRISPR-Cpf1 instead of the Cas9 protein in September 2017. These researchers also hope to have found an even better cutting protein.

 

Are you looking for protection of your patents?

Please take your chance and contact us. You can request a non-binding call-back at:

CAT-call_en

 

Souces:

Science News

Patent on CRISP-Cpf1

Letter Nature on New CRISP System

Pictures:

katjakuitunen /pixabay.com / CCO License  || Thomas-Suisse /pixabay.com / CCO License  

  • share  
  • share 
  • share 
  • share 
  • share 

Category iconHealthcare & Lifesciences,  Licenses,  Patent Law Tag iconBoard Institute,  CRISP,  Crispr,  Emmanuelle Charpentier,  EU-Patent,  Feng Zhang,  Jennifer Douda,  Patent,  U.S.,  USPTO

Primary Sidebar

More articles about: Healthcare & Lifesciences

All articles

Blog Menu

  • Design Law
  • Healthcare & Lifesciences
  • International Intellectual Property
  • Licenses
  • News from our law firm
  • Overall
  • Patent Law
  • Product- and Trademark piracy
  • Trademark Law

Recent Posts

  • What is the public allowed to know? 3. June 2024
  • BPatG: Patent claim of cancer drug on active substance as salt 7. March 2022
  • Grant for European IP Protection: SME Fund 2022 4. March 2022
  • CODE-X vs. Cody’s: Likelihood of confusion in drinks? 25. February 2022

Fields of Law

  • Patent Law
  • Utility Model Law
  • Employees’ Inventions
  • Trademark Law
  • Design Law
  • Trademark and Product Piracy
  • Expert Opinions
  • Costs

Das könnte Sie auch interessieren:

7. March 2022
BPatG: Patent claim of cancer drug on active substance as salt

BPatG: Patent claim of cancer drug on active substance as salt

4. March 2022
Grant for European IP Protection: SME Fund 2022

Grant for European IP Protection: SME Fund 2022

22. February 2022
PAP is in force: UPC possible in 2022

PAP is in force: UPC possible in 2022

8. February 2022
Germany: Value in dispute and costs in proceedings

Germany: Value in dispute and costs in proceedings

3. February 2022
PCT application – does the principle of joint applicants apply?

PCT application – does the principle of joint applicants apply?

1. February 2022
Proof of patent infringement by whistleblower

Proof of patent infringement by whistleblower

Contact us or request a call back

+49 (0) 69 / 606 278 – 0
[email protected]
Request a call back

Footer

Contact

Hanauer Landstrasse 287
D – 60314 Frankfurt am Main
Deutschland
+49 (0) 69 / 606 278 – 0
+49 (0) 69 / 606 278 – 199
[email protected]

Office Hours
Moday – Friday:   08:00-18:00

Fields of Law

  • Patent Law
  • Utility Model Law
  • Employees’ Inventions
  • Trademark Law
  • Design Law
  • Trademark and Product Piracy
  • Expert Opinions
  • Costs

Law Firm

  • Request non-binding call back
  • Company
  • Our Law Firm
  • ISO Certificate
  • Privacy Policy
  • Data handling for clients
  • Imprint

Follow Us

  • Facebook
  • Twitter
  • LinkedIn
  • xing
  • Email

Newsletter Signup

Newsletter INT

© Meyer-Dulheuer MD Legal Patentanwälte PartG

Contact Form

 

Give us a call, send us an email or fill out the contact form.

+49 (0) 69 / 606 278 – 0
[email protected]

Rückruf INT

Please note: If we deal specifically with your individual case, this is what is known as an initial consultation. In accordance with Section 34 of the Rechtsanwaltsvergütungsgesetz, this incurs one-off costs of 190 euros plus MwSt. We will be happy to assist you in a personal consultation after our telephone call.

Kontaktformular

 

Rufen Sie uns an, schicken Sie uns eine Mail oder füllen Sie das Kontaktformular aus.

+49 (0) 69 / 606 278 – 0
[email protected]

Rückruf

Um dieses Angebot nutzen zu können, müssen Sie der Speicherung Ihrer personenbezogenen Daten zustimmen. Wir behandeln diese streng vertraulich und verwenden sie nur zur Kontaktaufnahme mit Ihnen. Mehr dazu lesen Sie in unserer Datenschutzerklärung.

Bitte beachten Sie: Wenn wir uns konkret mit Ihrem Einzelfall befassen, ist dies eine sogenannte Erstberatung. Für eine solche entstehen gemäß § 34 Rechtsanwaltsvergütungsgesetz einmalige Kosten in Höhe von 190 Euro plus MwSt. Gerne helfen wir Ihnen im Anschluss an unser Telefonat in einem persönlichen Beratungsgespräch weiter.